Table 4

NOACs currently recommended for anticoagulation in patients with a confirmed PE diagnosis

Pharmacological agentReversal agentAdvantagesDisadvantages
ApixabanAndexanetRapid action (1–2 h). 
Reduction of VTE recurrence or death compared with placebo.
Contraindicated in case of severe hepatic insufficiency or CrCl<15 mL·min−1.
Interacts with CYP3A4 and P-gp inducers and inhibitors.
DabigatranIdarucizumabSuperior to warfarin for the prevention of recurrent VTE or VTE-related death.Concomitant treatment with P-gp inhibitors, inducers and tacrolimus is contraindicated.
Contraindicated if CrCl<30 mL·min−1.
EdoxabanAndexanetOnce-daily dosing can be used.
Superior to warfarin for the prevention of stroke and major bleeding.
Contraindicated in severe hepatic impairment or CrCl<15 mL·min−1.
Modified dosage when given concomitantly with P-gp inhibitors.
RivaroxabanAndexanet70% reduction in recurrent VTE compared with aspirinContraindicated in case of moderate or severe hepatic impairment or CrCl<30 mL·min−1.
Not recommended concomitantly with CYP3A4 and P-gp inhibitors.

CrCl: creatinine clearance; P-gp: P-glycoprotein.